919 related articles for article (PubMed ID: 12416447)
21. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
22. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
23. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
Arastéh K; Rieger A; Yeni P; Pozniak A; Boogaerts G; van Heeswijk R; de Béthune MP; Peeters M; Woodfall B
Antivir Ther; 2009; 14(5):713-22. PubMed ID: 19704175
[TBL] [Abstract][Full Text] [Related]
24. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
25. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
26. A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm.
Lange J
Antivir Ther; 2001; 6 Suppl 3():45-54. PubMed ID: 11678472
[TBL] [Abstract][Full Text] [Related]
27. Essential benefits of nucleoside analogue regimens in failing therapy.
Geretti AM
J HIV Ther; 2004 May; 9(2):28-33. PubMed ID: 15238873
[TBL] [Abstract][Full Text] [Related]
28. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
30. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
31. [Non-nucleoside reverse transcriptase inhibitors].
Joly V; Yeni P
Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
[TBL] [Abstract][Full Text] [Related]
33. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes.
Tamalet C; Fantini J; Tourres C; Yahi N
AIDS; 2003 Nov; 17(16):2383-8. PubMed ID: 14571191
[TBL] [Abstract][Full Text] [Related]
34. Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
Barreiro P; García-Benayas T; Soriano V; Gallant J
AIDS Rev; 2002; 4(4):233-41. PubMed ID: 12555697
[TBL] [Abstract][Full Text] [Related]
35. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
36. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Furrer H; Telenti A; Hirschel B; Vernazza PL; Bernasconi E; Rickenbach M; Perrin L; Ledergerber B; Günthard HF;
Arch Intern Med; 2007 Sep; 167(16):1782-90. PubMed ID: 17846398
[TBL] [Abstract][Full Text] [Related]
37. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
38. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.
Violin M; Forbici F; Cozzi-Lepri A; Velleca R; Bertoli A; Riva C; Giannella S; Manconi PE; Lazzarin A; Pasquinucci S; Tacconi L; Carnevale G; Mazzotta F; Bonazzi L; Montroni M; Chirianni A; Capobianchi M; Ippolito G; Moroni M; Perno CF; D'Arminio-Monforte A;
J Biol Regul Homeost Agents; 2002; 16(1):37-43. PubMed ID: 12003172
[TBL] [Abstract][Full Text] [Related]
39. Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
Waters LJ; Nelson MR
Int J Clin Pract; 2005 Dec; 59(12):1452-8. PubMed ID: 16351678
[TBL] [Abstract][Full Text] [Related]
40. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
